Gotowe bibliografie tematyczne / Pharmacology

Gotowa bibliografia na temat „Pharmacology”

Autor: Grafiati
Data publikacji: 4 czerwca 2021
Data aktualizacji: 30 lipca 2024

Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych

Wybierz rodzaj źródła:

Spis treści

Zobacz listy aktualnych artykułów, książek, rozpraw, streszczeń i innych źródeł naukowych na temat „Pharmacology”.

Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.

Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.

Artykuły w czasopismach na temat "Pharmacology"

1

Mortin, Lawrence I., Christopher J. Horvath i Michael S. Wyand. "Safety Pharmacology Screening: Practical Problems in Drug Development". International Journal of Toxicology 16, nr 1 (styczeń 1997): 41–65. http://dx.doi.org/10.1080/109158197227350.

Pełny tekst źródła
Streszczenie:
Undesired pharmacologic activities of novel drugs or biologies may limit development of a therapeutic prior to the characterization of any toxicologic effects. In rodent species, general pharmacology assays have traditionally been used to screen new agents for pharmacologic effects on the central and peripheral nervous systems, the autonomic nervous system and smooth muscles, the respiratory and cardiovascular systems, the digestive system, and the physiologic mechanisms of water and electrolyte balance. In large animal species, such as dogs and nonhuman primates, smaller numbers of animals per study limit their use for screening assays, but these species may play an important role in more detailed mechanistic studies. For drugs and biologies that must be tested in nonhuman primates because of species-specific action of the test agent, functional pharmacologic data are often collected during acute or subacute toxicity studies. This requires careful experimental design to minimize any impact pharmacologic effects or instrumentation may have on the assessment of toxicity. In addition, with many new therapies targeted at immunologic diseases, the pharmacologic effect of therapeutics on the immune system presents new challenges for pharmacologic profiling. The application of pharmacology assays by organ system in both rodent and large animal species are discussed, as well as practical issues in assessing pharmacology endpoints in the context of toxicity studies.
Style APA, Harvard, Vancouver, ISO itp.
2

Hite, Mark. "Safety Pharmacology Approaches". International Journal of Toxicology 16, nr 1 (styczeń 1997): 23–31. http://dx.doi.org/10.1080/109158197227332.

Pełny tekst źródła
Streszczenie:
This article presents views of a discipline termed safety pharmacology or general pharmacology. This is an area that provides information through empirical studies on new pharmacologic agents at doses above those thought to be efficacious and the no-toxicologic-effect level (NOEL) above which unwanted effects might occur. The usefulness of batteries of tests is discussed, and comments are made about the value of these in the drug developmental process.
Style APA, Harvard, Vancouver, ISO itp.
3

Teixeira, Marcus Zulian. ""˜Paradoxical pharmacology": therapeutic strategy used by the "˜homeopathic pharmacology" for more than two centuries". International Journal of High Dilution Research - ISSN 1982-6206 13, nr 49 (24.10.2021): 207–26. http://dx.doi.org/10.51910/ijhdr.v13i49.714.

Pełny tekst źródła
Streszczenie:
Using the empirical or phenomenological research method by observing the effects of drugs in the human physiology, Samuel Hahnemann proposed the homeopathic treatment. He synthesized modern pharmacodynamic in the ‘primary action’ of the drugs and in the consequent and opposite ‘secondary action’ or ‘vital reaction’ of the organism. Noting that drugs with ‘contrary’ primary action to the symptoms of the diseases caused worsening of the symptoms after its withdrawal, as a result of secondary action of the organism, Hahnemann proposed using this vital reaction in a curative way, administering to sick individuals the drugs that caused ‘similar’ symptoms in healthy individuals (therapeutic use of the similitude principle). According to the clinical and experimental pharmacology, this secondary action (vital reaction) of the organism is observed in the ‘rebound effect’ or ‘paradoxical reaction’ of several classes of drugs, which is the scientific basis of the ‘homeopathic pharmacology’. In the last decade, exponents of modern pharmacology have suggested the therapeutic use of the paradoxical reaction (‘paradoxical pharmacology’), proposing the use of drugs that cause an exacerbation of the disease in the short term to treat these same diseases in the long-term. In this review, we compare the various aspects between the ‘homeopathic pharmacology’ and the ‘paradoxical pharmacology’, reinforcing the validity of homeopathic assumptions and expanding the knowledge to optimize both proposals.
Style APA, Harvard, Vancouver, ISO itp.
4

Sepúlveda, Pablo O., Valeria Epulef i Gustavo Campos. "Why do We Use the Concepts of Adult Anesthesia Pharmacology in Developing Brains? Will It Have an Impact on Outcomes? Challenges in Neuromonitoring and Pharmacology in Pediatric Anesthesia". Journal of Clinical Medicine 10, nr 10 (18.05.2021): 2175. http://dx.doi.org/10.3390/jcm10102175.

Pełny tekst źródła
Streszczenie:
Background: Pediatric sedation and anesthesia techniques have plenty of difficulties and challenges. Data on the pharmacologic, electroencephalographic, and neurologic response to anesthesia at different brain development times are only partially known. New data in neuroscience, pharmacology, and intraoperative neuromonitoring will impact changing concepts and clinical practice. In this article, we develop a conversation to guide the debate and search for a view more attuned to the updated knowledge in neurodevelopment, electroencephalography, and clinical pharmacology for the anesthesiologic practice in the pediatric population.
Style APA, Harvard, Vancouver, ISO itp.
5

Mahmoud, Jahangir. "Clinical pharmacology of anxiolytics". Psychology and Mental Health Care 2, nr 1 (27.03.2018): 01–04. http://dx.doi.org/10.31579/2637-8892/022.

Pełny tekst źródła
Streszczenie:
It is increasingly difficult to define what an anxiolytic is, since anxiety is multiple although many symptoms are common. On the other hand the most used drugs in different forms of anxiety were first used as antidepressants. This article tries to put together the different effective anxiolytics used and describe their pharmacology.
Style APA, Harvard, Vancouver, ISO itp.
6

Adi Try Wurjatmiko. "The Effects of Music Therapy Intervention on the Pain and Anxiety Levels of Cancer Patient: A Systematic Review". International Journal of Nursing Education 11, nr 4 (21.11.2019): 14–18. http://dx.doi.org/10.37506/ijone.v11i4.3936.

Pełny tekst źródła
Streszczenie:
Cancer constitutes one of illnesses which frequently causes pain and anxiety. The management of cancer pain comprises the pharmacology and non-pharmacology. The pharmacologic management, at some points, fails to provide a complete relief from the pain and instead gives rises to unwanted side-effects on the patients that necessitate the employment of non-pharmacologic management such as music therapy. The purpose of this systematic review is to discover the effects of music therapy on the pain and anxiety levels on the cancer patient. Systematic Review encompasses literature obtained from library research and internet research using search engine such as PubMed, Medline, Proquest, dan Elsevier. The articles comprise the full text journals published between the years of 2009-2016. 87.50% out of 8 articles (1 systematic review) demonstrates that music therapy effectively alleviates the pain to 75.00% and lowers the anxiety level, and 12.50% of insignificant palliative effect in terms of the pain and anxiety. Music therapy is an effective non-pharmacologic therapy to alleviate or relieve the cancer patients of the resultant pain and anxiety.
Style APA, Harvard, Vancouver, ISO itp.
7

Wall, Nathan R., Ryan N. Fuller, Ann Morcos i Marino De Leon. "Pancreatic Cancer Health Disparity: Pharmacologic Anthropology". Cancers 15, nr 20 (20.10.2023): 5070. http://dx.doi.org/10.3390/cancers15205070.

Pełny tekst źródła
Streszczenie:
Pancreatic cancer (PCa) remains a formidable global health challenge, with high mortality rates and limited treatment options. While advancements in pharmacology have led to improved outcomes for various cancers, PCa continues to exhibit significant health disparities, disproportionately affecting certain populations. This paper explores the intersection of pharmacology and anthropology in understanding the health disparities associated with PCa. By considering the socio-cultural, economic, and behavioral factors that influence the development, diagnosis, treatment, and outcomes of PCa, pharmacologic anthropology provides a comprehensive framework to address these disparities and improve patient care.
Style APA, Harvard, Vancouver, ISO itp.
8

Anand Dhonde, Shreya, i Rahul Sudam Jadhav. "New Developments in Behavioural Pharmacology". International Journal of Science and Research (IJSR) 12, nr 10 (5.10.2023): 117–21. http://dx.doi.org/10.21275/mr23928202832.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
9

Pupo, Andre S., i Kenneth P. Minneman. "Adrenergic Pharmacology: Focus on the Central Nervous System". CNS Spectrums 6, nr 8 (sierpień 2001): 656–62. http://dx.doi.org/10.1017/s1092852900001346.

Pełny tekst źródła
Streszczenie:
ABSTRACTNorepinephrine and epinephrine are involved in the control of several important functions of the central nervous system (CNS), including sleep, arousal, mood, appetite, and autonomic outflow. Catecholamines control these functions through activation of a family of adrenergic receptors (ARs). The ARs are divided into three subfamilies (α1, α2, and β) based on their pharmacologic properties, signaling mechanisms, and structure. ARs in the CNS are targets for several therapeutic agents used in the treatment of depression, obesity, hypertension, and other diseases. Not much is known, however, about the role of specific AR sub-types in the actions of these drugs. In this paper, we provide an overview of adrenergic pharmacology in the CNS, focusing on the pharmacologic properties of subtype-selective AR agonists and antagonists, the accessibility of these drugs to the CNS, and the distribution of ARs in different areas of the brain.
Style APA, Harvard, Vancouver, ISO itp.
10

Karlsen Bjånes, Tormod, Espen Mjåset Hjertø, Lars Lønne, Lena Aronsen, Jon Andsnes Berg, Stein Bergan, Grim Otto Berg-Hansen i in. "Pharmacology Portal: An Open Database for Clinical Pharmacologic Laboratory Services". Clinical Therapeutics 38, nr 1 (styczeń 2016): 222–26. http://dx.doi.org/10.1016/j.clinthera.2015.10.015.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
Więcej źródeł

Rozprawy doktorskie na temat "Pharmacology"

1

Riba, Serrano Jordi. "Human pharmacology of ayahuasca". Doctoral thesis, Universitat Autònoma de Barcelona, 2003. http://hdl.handle.net/10803/5378.

Pełny tekst źródła
Streszczenie:
La ayahuasca es una bebida psicotrópica obtenida de las plantas Banisteriopsis caapi y Psychotria viridis, que ha sido utilizada desde hace siglos en las cuencas de los ríos Amazonas y Orinoco con finalidades mágico-religiosas y en la medicina tradicional de estas áreas geográficas. La bebida contiene alcaloides que muestran actividad inhibidora del enzima monoamino oxidasa o MAO (harmina, harmalina y tetrahidroharmina) y un compuesto alucinógeno (la N,N-dimetiltriptamina o DMT) que es inactivo por vía oral en ausencia de los anteriores. El consumo de ayahuasca se ha ido popularizando lentamente en Europa desde principios de la década de los 90. Dada la escasa información existente sobre los efectos de la ayahuasca en humanos, se llevaron a cabo dos estudio clínicos con voluntarios sanos a los que se administraron distintas dosis de ayahuasca liofilizada y encapsulada. En un primer estudio piloto se administraron en orden creciente un placebo y tres dosis de ayahuasca correspondientes a 0.50, 0.75 y 1.0 mg DMT/kg peso a 6 voluntarios sanos en condiciones de simple ciego. En el estudio final se administraron de forma aleatorizada y balanceada un placebo y dos dosis de ayahuasca correspondientes a 0.6 y 0.85 mg DMT/kg peso a 18 voluntarios sanos en condiciones de doble ciego. Las variables estudiadas incluyeron medidas de efectos subjetivos, medidas cardiovasculares, farmacocinética, niveles de metabolitos de neurotransmisores en orina, registros de electroencefalografía (EEG), potenciales evocados (supresión del potencial auditivo P50) y electromiografía (supresión del reflejo de sobresalto). La ayahuasca produjo efectos subjetivos de activación, bienestar y euforia, cambios en la percepción somática y visual y cambios en el contenido y velocidad del pensamiento. Los efectos subjetivos máximos se observaron a los 60-120 minutos y desaparecieron a las 4-6 horas postadministración. Los efectos cardiovasculares fueron moderados con incrementos estadísticamente significativos únicamente en la presión arterial diastólica (9 mm Hg a los 75 minutos tras la dosis de 0.85 mg DMT/kg). El estudio farmacocinético determinó la presencia en plasma de DMT, harmalina y THH, pero no de harmina. Se midieron así mismo niveles de dos compuestos O-demetilados, harmol y harmalol, metabolitos de la harmina y la harmalina, respectivamente. Las concentraciones máximas de DMT fueron de 12.14 ng/ml y 17.44 ng/ml tras las dosis de 0.6 y 0.85 mg DMT/kg, respectivamente. Estas concentraciones se obtuvieron a los 90 minutos postadministración tras ambas dosis. La semivida de eliminación de la DMT fue de 1 hora tras ambas dosis. Se estimó la biodisponibilidad de la DMT tras la administración de ayahuasca en un 10-15%. La administración de ayahuasca produjo un aumento en la excreción de normetanefrina, metabolito de la noradrenalina COMT-dependiente, sin que se evidenciaran disminuciones en la excreción de metabolitos MAO-dependientes. A nivel del EEG, se observaron disminuciones en el valor de potencia absoluta para las bandas delta, teta, alfa-2 y beta-1. Estas disminuciones fueron máximas a la 1-2 horas postadministración. La aplicación de una técnica de localización de los cambios observados en el EEG mostró disminuciones de densidad de potencia a nivel intracerebral en el córtex temporo-parieto-occipital, frontomedial y temporomedial. Finalmente, la administración de ayahuasca produjo disminuciones en la tasa de supresión del potencial auditivo P50 (paradigma utilizado para determinar el grado de supresión sensorial), pero no en la tasa de supresión del reflejo de sobresalto por un preestímulo (paradigma utilizado para determinar el grado de supresión sensoromotora). Los resultados obtenidos ponen de manifiesto que la ayahuasca muestra un patrón de efectos alucinógenos y psicoestímulantes análogos a los reportados por otros autores para la DMT administrada por vía parenteral, pero de menor intensidad y duración más prolongada.
Ayahuasca is a psychotropic plant tea, obtained from Banisteriopsis caapi and Psychotria viridis, which has been used for centuries in the Amazon and Orinoco River Basins for magico-religious purposes and folk medicine. This tea contains alkaloids with monoamine-oxidase (MAO)-inhibiting properties (harmine, harmaline and tetrahydroharmine), together with a psychedelic compound (N,N-dimethyltryptamine or DMT), which is inactive per os in the absence of the first three. The use of ayahuasca has gradually spread to Europe since the early 1990s, and given the scarce information available on the effects of ayahuasca in humans, two clinical trials were conducted in healthy volunteers, who were administered various doses of encapsulated freeze-dried ayahuasca. In an initial pilot study, a placebo and three doses of ayahuasca equivalent to 0.50, 0.75 and 1.0 mg DMT/kg body weight were administered in increasing order to 6 healthy volunteers in single-blind conditions. In a subsequent study, a placebo and two doses of ayahuasca equivalent to 0.6 and 0.85 mg DMT/kg were administered to 18 healthy volunteers according to a double-blind randomized balanced design. The studied variables included measures of subjective and cardiovascular effects, pharmacokinetic parameters, urine neurotransmitter metabolites, electroencephalography recordings (EEG), evoked potentials (suppression of the auditive P50 potential) and electromyography (suppression of the startle reflex). Ayahuasca induced subjective feelings of increased activation, euphoria and well-being, modifications in somatic and visual perception, and also in thought content and speed. Peak subjective effects were observed between 60-120 minutes and were resolved by 4-6 hours. Cardiovascular effects were moderate, with statistically significant increases obtained only for diastolic blood pressure (9 mm Hg at 75 minutes after the 0.85 mg DMT/kg dose). The pharmacokinetic assessment revealed measurable plasma levels for DMT, harmaline and THH, but not for harmine. Levels of two O-demethylated compounds, i.e., harmol and harmalol, putative metabolites of harmine and harmaline, respectively, were detected in all volunteers. Cmax values for DMT after the low and the high ayahuasca doses were 12.14 ng/ml and 17.44 ng/ml, respectively. Tmax was observed at 90 minutes after both doses. Elimination half-life for DMT was 1 hour after both doses. DMT bioavailability in ayahuasca was estimated in 10-15%. Ayahuasca administration increased normetanephrine excretion, a COMT-dependent norepinephrine metabolite, and produced no change in the excretion of MAO-dependent metabolites. Regarding the EEG, decreases in absolute power were obtained for the delta, theta, alpha-2 and beta-1 bands. These decreases were maximal at 1-2 hours. The application of a source location technique to the topographical changes obtained, yielded intracerebral power density decreases in the temporo-parieto-occipital, frontomedial and temporomedial cortices. Finally, ayahuasca decreased suppression of the P50 potential (measuring sensory gating), but did not change prepulse inhibition of the startle reflex (measuring sensorimotor gating). The results obtained indicate for ayahuasca a pattern of psychedelic and stimulatory effects analogous to those reported by other authors for parentheral DMT, but with a lower intensity and a longer duration.
Style APA, Harvard, Vancouver, ISO itp.
2

Cumming, Paul Kenneth. "Pharmacology of cerebral histamine". Thesis, University of British Columbia, 1990. http://hdl.handle.net/2429/30687.

Pełny tekst źródła
Streszczenie:
Four aspects of the function of histaminergic systems were studied in the rat brain: toxicology, catabolism, release in vivo, and high affinity binding of histamine. Preparations of histamine-N-methyltransferase (HNMT) derived from kidney and brain were employed in the radioenzymatic quantification of histamine in biological samples. Tritiated S-adenosyl-L-methionine ([³H]-SAM) served as the co-substrate. A toxicological study was conducted to determine the sensitivity of the HA innervation to prenatal treatment with methylazoxymethanol (MAM), an inhibitor of mitosis. In adult rats, the MAM treatment was without effect on cerebral histamine content, although forebrain HNMT activity was 50% reduced. In another study, C-57 mice were treated with the selective dopamine neurotoxin l-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Substantial dopamine depletions were not associated with alterations in the cerebral histamine content. In a study of the structural requirements for HNMT inhibition, 9-amino-1,2,3,4-tetrahydroacridine (THA), was found to be one of the most potent inhibitors yet described. The β-carboline alkaloids, of which harmaline is the prototype, were also found to be moderately potent HNMT inhibitors. Because of the lack of high-affinity re-uptake and the absence of alternate catabolic pathways, blockade of HNMT can potentially alter central histaminergic tone. Peripheral administration of THA was able to produce dose-dependent increases in cerebral histamine content, as was the more potent HNMT inhibitor, metoprine. The issue of structural requirements for HNMT inhibition are discussed in the light of these results. The in vivo release of histamine was studied by the cerebral microdialysis technique. After chronic implantation of horizontal probes, TTX-insensitive and partially calcium-sensitive efflux of histamine was detected in the dorsal striatum and the bed nucleus of the stria terminalis. In striatum, histamine efflux was elevated 50% after peripheral histidine loading (500 mg/kg, i.p.). After synthesis blockade with α-fluoromethylhistidine (100 mg/kg,i.p.), extracellular histamine levels in striatum disappeared in a bi-exponential manner. The half-lives of this disappearance, 32 minutes and 7 hours, indicate the presence of at least two histamine pools. Striatal histamine efflux was elevated by yohimbine treatment (10 mg/kg, i.p.), suggesting the presence of a tonic α₂-adrenergic inhibition of histamine release in vivo. In addition to the classical H₁ and H₂ receptors, histamine is able to bind to a pharmacologically distinct site, H₃, recently characterized as an autoreceptor regulating the synthesis and release of histamine. The binding properties of the H₃ ligand [³H]-N[symbol omitted]-methylhistamine ([³H]-N-MeHA) were studied in forebrain cryostat sections by autoradiography. Determination of Bmax (25 fmole/section) and displacement studies indicated that [³H]-N-MeHA bound to the same site as [³H]-histamine: the high affinity histamine binding site. Binding was greatest in the basal ganglia and had a complex distribution within the cerebral cortex. Quinolinic acid lesion studies indicated that the majority of the binding in the basal ganglia was on striato-nigral projection neurons. Cortical binding was also sensitive to local excitotoxic lesions. Therefore, the majority of H₃ binding is located on postsynaptic structures intrinsic to these brain regions, rather than on presynaptic autoreceptors on terminals of histamine neurons.
Medicine, Faculty of
Graduate
Style APA, Harvard, Vancouver, ISO itp.
3

Karbwang, J. "Clinical pharmacology of mefloquine". Thesis, University of Liverpool, 1987. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.234865.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
4

Ordway, Gregory A. "Molecular Pharmacology of Antidepressants". Digital Commons @ East Tennessee State University, 2006. https://dc.etsu.edu/etsu-works/8657.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
5

Langford, Nigel James. "Beta-receptor pharmacology and therapeutics". Thesis, University of Birmingham, 2003. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.404060.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
6

Hahn, Robert G. "Clinical pharmacology of infusion fluids". Linköpings universitet, Anestesiologi med intensivvård, 2012. http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-91319.

Pełny tekst źródła
Streszczenie:
Fluids are used for intravenous infusion during practically all surgeries, but several different compositions are available on the market. Crystalloid fluids comprise lactated or acetated Ringer solutions, normal saline, Plasma-Lyte, hypertonic saline, and glucose. They lack allergic properties but are prone to cause peripheral tissue oedema. Their turn­ over is governed by physiological factors such as dehydration and drug effects. Colloid fluids include hydroxyethyl starch, albumin, dextran, and gelatin. These fluids have various degrees of allergic properties and do not promote peripheral oedema. Their half-life is usually about hours. Factors increasing the turnover rate are poorly known but might include inflammatory states. Current debates include the widespread use of normal saline, which should be replaced by Ringer’s or Plasma-Lyte in most situations, and the kidney damage associated with the use of starch in septic patients. New studies show that hypertonic saline does not improve survival or neurological damage in prehospital care.
Style APA, Harvard, Vancouver, ISO itp.
7

Farquhar, Michelle Jane. "Molecular pharmacology of chimeric peptides". Thesis, University of Wolverhampton, 2002. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.247780.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
8

Pasanisi, F. "Clinical pharmacology of calcium antagonists". Thesis, University of Glasgow, 1986. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.381477.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
9

Al-Malki, Waleed Hassan. "Pharmacology of aqueous humour formation". Thesis, University of Glasgow, 2006. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.443403.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
10

Ward, S. A. "The biochemical pharmacology of primaquine". Thesis, University of Liverpool, 1985. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.354530.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
Więcej źródeł

Książki na temat "Pharmacology"

1

Katzung, Bertram G. Basic and clinical pharmacology. Wyd. 3. Norwalk, Conn: Appleton & Lange, 1987.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
2

G, Katzung Bertram, red. Basic and clinical pharmacology. Wyd. 4. London: Prentice-Hall, 1989.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
3

A, Harvey Richard, Champe Pamela C, Mycek Mary Julia, Gertner Sheldon B i Perper Maria Menna, red. Pharmacology. Philadelphia: Lippincott, 1992.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
4

Gallelli, Luca. Pharmacology. Rijeka: InTech, 2012.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
5

Hadden, John W., i Andor Szentivanyi, red. Pharmacology. Boston, MA: Springer US, 1985. http://dx.doi.org/10.1007/978-1-4615-9406-2.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
6

Moore, Joanne I., red. Pharmacology. New York, NY: Springer US, 1987. http://dx.doi.org/10.1007/978-1-4684-0280-3.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
7

Moore, Joanne I., red. Pharmacology. New York, NY: Springer US, 1990. http://dx.doi.org/10.1007/978-1-4684-0353-4.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
8

Moore, Joanne I., red. Pharmacology. New York, NY: Springer US, 1992. http://dx.doi.org/10.1007/978-1-4684-0524-8.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
9

Moore, Joanne I., red. Pharmacology. New York, NY: Springer New York, 1995. http://dx.doi.org/10.1007/978-1-4612-2514-0.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
10

McCuistion, Linda E. Pharmacology. Wyd. 2. St. Louis, Mo: Saunders/Elsevier, 2007.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
Więcej źródeł

Części książek na temat "Pharmacology"

1

Wahl, Wendy L., i James T. Miller. "Pharmacology". W Geriatric Trauma and Critical Care, 345–52. New York, NY: Springer New York, 2013. http://dx.doi.org/10.1007/978-1-4614-8501-8_34.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
2

Amin, Hardik P., i Joseph L. Schindler. "Pharmacology". W Vascular Neurology Board Review, 235–41. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-52552-1_19.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
3

Martin, Jennifer H. "Pharmacology". W Geriatric Medicine, 43–57. Singapore: Springer Singapore, 2017. http://dx.doi.org/10.1007/978-981-10-3253-0_4.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
4

Chard, Tim, i Richard Lilford. "Pharmacology". W Basic Sciences for Obstetrics and Gynaecology, 163–86. London: Springer London, 1986. http://dx.doi.org/10.1007/978-1-4471-3327-8_7.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
5

Chard, Tim, i Richard Lilford. "Pharmacology". W MRCOG Part I, 102–14. London: Springer London, 1987. http://dx.doi.org/10.1007/978-1-4471-3335-3_7.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
6

Chard, Tim, i Richard Lilford. "Pharmacology". W Basic Sciences for Obstetrics and Gynaecology, 166–91. London: Springer London, 1990. http://dx.doi.org/10.1007/978-1-4471-3340-7_7.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
7

Chard, Tim, i Richard Lilford. "Pharmacology". W Basic Sciences for Obstetrics and Gynaecology, 165–90. London: Springer London, 1995. http://dx.doi.org/10.1007/978-1-4471-3372-8_7.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
8

Chard, Tim, i Richard Lilford. "Pharmacology". W MRCOG Part I, 108–20. London: Springer London, 1992. http://dx.doi.org/10.1007/978-1-4471-3884-6_7.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
9

Sheff, Emily J. Karwacki, James L. Januzzi i James L. Januzzi. "Pharmacology". W MGH Cardiology Board Review, 533–44. London: Springer London, 2013. http://dx.doi.org/10.1007/978-1-4471-4483-0_33.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
10

Hill, Sue. "Pharmacology". W Competency-Based Critical Care, 1–11. London: Springer London, 2010. http://dx.doi.org/10.1007/978-1-84996-146-2_1.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.

Streszczenia konferencji na temat "Pharmacology"

1

Posadas, Inmaculada, i María Pérez. "DISCOVERING PHARMACOLOGY". W 13th International Conference on Education and New Learning Technologies. IATED, 2021. http://dx.doi.org/10.21125/edulearn.2021.0847.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
2

Mahran, Rama, Pan Shu, Duxin Sun i Dean E. Brenner. "Abstract 5257: Cellular pharmacology of curcumin cellular pharmacology of curcumin±piperine". W Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.am2017-5257.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
3

Eldeeb, Khalil. "ASPET Academy of Pharmacology Educators: Twelve Years of Pharmacology Educators’ Recognition". W ASPET 2023 Annual Meeting Abstracts. American Society for Pharmacology and Experimental Therapeutics, 2023. http://dx.doi.org/10.1124/jpet.122.568160.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
4

Borodin, Yuriy I., Lybov N. Rachkovskaya, Tatyana V. Popova, Anastasiya A. Kotlyarova, Svetlana V. Michurina, Anna V. Shurlygina, Edmund E. Rachkovskiy i in. "Modified Sorbents for Pharmacology". W 2018 11th International Multiconference Bioinformatics of Genome Regulation and Structure\Systems Biology (BGRS\SB). IEEE, 2018. http://dx.doi.org/10.1109/csgb.2018.8544763.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
5

"NOVEL ANTIBIOTICS IN PHARMACOLOGY". W ТРАДИЦІЙНІ ТА ІННОВАЦІЙНІ ПІДХОДИ ДО НАУКОВИХ ДОСЛІДЖЕНЬ. Міжнародний центр наукових досліджень, 2020. http://dx.doi.org/10.36074/10.04.2020.v2.12.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
6

Negus, Sidney, i James Percy. "The VCU Virtual Pharmacology Lab: An Online Tool for Graduate Pharmacology Education". W ASPET 2024 Annual Meeting Abstract. American Society for Pharmacology and Experimental Therapeutics, 2024. http://dx.doi.org/10.1124/jpet.217.905710.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
7

Tuinier, Siegfried, i Willem M. A. Verhoeven. "BEHAVIORAL PHARMACOLOGY OF SELF-INJURY". W IX World Congress of Psychiatry. WORLD SCIENTIFIC, 1994. http://dx.doi.org/10.1142/9789814440912_0016.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
8

Dzagakhova, Agunda Vladimirovna, i Laura Paatovna Dzhabieva. "Pharmacology relevance of prion diseases". W International Research-to-practice Conference for students. TSNS Interaktiv Plus, 2016. http://dx.doi.org/10.21661/r-115103.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
9

de Lacerda, Dhiego Alves, Pedro Fechine Honorato, Larissa Luana Lopes Lima, Anaylle Vieira Lacerda Oliveira, Eryclys Abreu de Lira, Francisca Evelyn Abreu de Lira, Joaquim Fernandes de Sousa Neto i in. "Comparative review: Efficacy of opioid versus non-opioid analgesic treatment in patients with acute pain in the emergency room". W VI Seven International Multidisciplinary Congress. Seven Congress, 2024. http://dx.doi.org/10.56238/sevenvimulti2024-109.

Pełny tekst źródła
Streszczenie:
Acute pain, a prevalent symptom in emergency contexts, often stems from trauma, surgical interventions, or acute medical conditions, requiring effective management to mitigate discomfort and prevent chronic sequelae. This study compares the efficacy, safety, and outcomes of opioid analgesic use compared to non-opioid analgesics in acute pain management in emergency settings. The systematic review includes data from databases such as SciELO and PubMed, as well as the critical analysis of reference works in pharmacology such as "Rang & Dale's Pharmacology", "Goodman & Gilman's: The Pharmacological Basis of Therapeutics" and "Lange's Basic & Clinical Pharmacology". The results show that while opioids offer immediate and potent relief from severe pain, non-opioids are often preferred due to a more benign safety profile.
Style APA, Harvard, Vancouver, ISO itp.
10

Popova, O. S. "Pharmacological effects of taxifolin (dihydroquercitin)." W SPbVetScience. FSBEI HE St. Petersburg SUVM, 2023. http://dx.doi.org/10.52419/3006-2023-8-68-71.

Pełny tekst źródła
Streszczenie:
Summary. Currently, native drugs are increasingly being used as an alternative to allopathic drugs. The article discusses the main regularities in the pharmacology of taxifolin, studied both at the Department of Pharmacology and Toxicology of the Federal State Budgetary Educational Institution of Higher Education, St. Petersburg State University of Medicine, and on the basis of literary sources of international databases.
Style APA, Harvard, Vancouver, ISO itp.

Raporty organizacyjne na temat "Pharmacology"

1

Lietman, Paul S., Brent G. Petty i David M. Kornhauser. Clinical Pharmacology Studies. Phase 1. Fort Belvoir, VA: Defense Technical Information Center, kwiecień 1989. http://dx.doi.org/10.21236/ada210900.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
2

Lietman, Paul S., i Brent G. Petty. Phase I Clinical Pharmacology Studies. Fort Belvoir, VA: Defense Technical Information Center, wrzesień 1993. http://dx.doi.org/10.21236/ada274199.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
3

Lietman, Paul S., i Brent G. Petty. Phase I Clinical Pharmacology Studies. Fort Belvoir, VA: Defense Technical Information Center, wrzesień 1993. http://dx.doi.org/10.21236/ada274200.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
4

Ozegovic, Agnes. Breaking Bad Pharmacology and Biochemical Science. Ames (Iowa): Iowa State University, maj 2023. http://dx.doi.org/10.31274/cc-20240624-314.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
5

Lynch, Gary, i M. Kessler. Chemistry and Pharmacology of Long Term Potentiation: Contributions Beyond Synaptic Modification. Fort Belvoir, VA: Defense Technical Information Center, czerwiec 2000. http://dx.doi.org/10.21236/ada379775.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
6

Izmozherova, Nadezdha, Viktor Bakhtin i Muraz Shambatov. Electronic training course "Pharmacology for students of the Faculty of Pharmacy". SIB-Expertise, grudzień 2022. http://dx.doi.org/10.12731/er0651.15122022.

Pełny tekst źródła
Streszczenie:
Электронный учебный курс «Фармакология для студентов фармацевтического факультета» составлен в соответствии с требованиями Федерального государственного образовательного стандарта высшего образования по специальности 33.05.01 Фармация, утвержденным приказом Министерства образования и науки Российской Федерации от 27 марта 2018 г. № 219, и с учетом требований профессионального стандарта 02.006 «Провизор», утвержденного приказом Министерства труда и социальной защиты Российской Федерации от 9 марта 2016 г. № 91н. Цель изучения курса - овладение студентами необходимым объемом теоретических и практических знаний по фармакологии для освоения выпускниками компетенций в соответствии с ФГОС ВО специальности 33.05.01 Фармация, способных и готовых к выполнению трудовых функций, требуемых профессиональным стандартом 02.006 «Провизор». Задачи курса: 1. Сформировать знания классификаций лекарственных препаратов, основных фармакологических характеристик лекарственных средств, фармакодинамики и фармакокинетики, показаний и противопоказаний к применению лекарственных средств, побочных эффектов, возникающих при применении лекарственных препаратов; 2. Научить анализировать действие лекарственных средств по совокупности их фармакологических свойств и возможность их использования для терапевтического лечения пациента; 3. Выработать навыки оформления рецептов, составления рецептурных прописей лекарственных препаратов и экспертизы рецептурных бланков; 4. Выработать составляющие компетенций, направленных на обучение и воспитание готовности и способности выпускников выполнять трудовые функции: охрану здоровья граждан путем обеспечения оказания медицинской помощи в соответствии с установленными требованиями и стандартами в сфере здравоохранения. Трудоемкость курса составляет 252 часа. Курс состоит из 51 дидактической единицы.
Style APA, Harvard, Vancouver, ISO itp.
7

Ștefănescu, Ruxandra, Eszter Laczkó-Zöld, Bianca-Eugenia Ősz i Camil-Eugen Vari. An updated systematic review of Vaccinium myrtillus leaves: phytochemistry and pharmacology. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, grudzień 2022. http://dx.doi.org/10.37766/inplasy2022.12.0029.

Pełny tekst źródła
Streszczenie:
Review question / Objective: This review aims to present the latest knowledge on the phytochemical profile as well as the therapeutic effects of Vaccinium myrtillus leaves. Background: The leaves are used in traditional medicine of different countries for the management of diabetes. Until date there are no relevant information, only assumptions regarding the compounds that are responsible for this effect Bilberry leaves are used in many countries in traditional medicine for treating a wide variety of diseases. Well documented in the literature, the influence of pedo-climatic conditions is an important factor that is responsible for the noticeable differences among the chemical composition of herbal drugs, and also the accumulation of different metals, having significant effects on the quality of plant products.
Style APA, Harvard, Vancouver, ISO itp.
8

Izmozherova, Nadezdha, Viktor Bakhtin, Marina Driker, Maria Dobrinskaya, Elena Safianik i Muraz Shambatov. Electronic training course "Pharmacology for students of General Medicine and Pediatric faculties". SIB-Expertise, grudzień 2022. http://dx.doi.org/10.12731/er0650.15122022.

Pełny tekst źródła
Streszczenie:
Электронный учебный курс «Фармакология для студентов лечебно-профилактического и педиатрического факультетов» составлен в соответствии с требованиями следующих документов: Федеральный государственный образовательный стандарт высшего образования по специальности 31.05.01 Лечебное дело, утверждённый приказом Министерства науки и высшего образования Российской Федерации от 12.08.2020 г. № 988 Федеральный государственный образовательный стандарт высшего образования по специальности 31.05.02 Педиатрия, утвержденный приказом Министерства науки и высшего образования Российской Федерации от 12.08.2020 г. № 965 Профессиональный стандарт ""Врач-лечебник (врач-терапевт участковый)"" , утвержденный приказом Министерства труда и социальной защиты Российской Федерации от 21.03.2017 г. № 293н Профессиональный стандарт ""Врач-педиатр участковый"", утверждённый приказом Министерства труда и социальной защиты Российской Федерации от 27.03.2017 г. № 306н Цель изучения курса - овладение студентами необходимым объемом теоретических и практических знаний по фармакологии для освоения компетенций в соответствии с требованиями Федеральных государственных образовательных стандартов высшего образования. Задачи курса: Освоение общих принципов оформления рецептов и составления рецептурных прописей, умения выписывать в рецептах различные лекарственные формы Знание общих закономерностей фармакокинетики и фармакодинамики лекарственных средств. Умение анализировать действия лекарственных средств по совокупности их фармакологических эффектов, механизмов и локализации действия, фармакокинетики Умение оценивать возможности использования лекарственных средств для целей фармакотерапии на основе представлений об их свойствах Приобретение навыков выписывать лекарственные средства в рецептах при определенных патологических состояниях, исходя из особенностей фармакодинамики и фармакокинетики лекарственных препаратов Трудоемкость курса составляет 252 часа.
Style APA, Harvard, Vancouver, ISO itp.
9

Munavalli, Shekar, Dennis K. Rohrbaugh i H. D. Durst. Chemistry, Biochemistry, Pharmacology, and Toxicology of CS and Synthesis of Its Novel Analogs. Fort Belvoir, VA: Defense Technical Information Center, październik 2007. http://dx.doi.org/10.21236/ada474594.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
10

Wang, Qin, Xinya Peng i Congchao Jia. Efficacy and Pharmacological Mechanism of Poria cocos-based Formulas Combined with Chemotherapy for Ovarian Cancer: A Integrated Systems Pharmacology Study. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, sierpień 2021. http://dx.doi.org/10.37766/inplasy2021.8.0060.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
Możesz być także zainteresowany rozszerzonymi bibliografiami na temat „Pharmacology” dla poszczególnych typów źródeł:
Artykuły w czasopismach Rozprawy doktorskie Książki
Oferujemy zniżki na wszystkie plany premium dla autorów, których prace zostały uwzględnione w tematycznych zestawieniach literatury. Skontaktuj się z nami, aby uzyskać unikalny kod promocyjny!

Do bibliografii